Efficacy classification of modern therapies in multiple sclerosis
The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines. Therapies were classified by...
Gespeichert in:
| Veröffentlicht in: | Journal of comparative effectiveness research 2021-04, Vol.10 (6), p.495-507 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 507 |
|---|---|
| container_issue | 6 |
| container_start_page | 495 |
| container_title | Journal of comparative effectiveness research |
| container_volume | 10 |
| creator | Samjoo, Imtiaz A Worthington, Evelyn Drudge, Christopher Zhao, Melody Cameron, Chris Häring, Dieter A Stoneman, Dee Klotz, Luisa Adlard, Nicholas |
| description | The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines.
Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate.
For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used.
Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy. |
| doi_str_mv | 10.2217/cer-2020-0267 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2492661755</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2515675347</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-8481713e994f470bb1ee66c67525618de5662d853bfa8bc986a91c99818d34c53</originalsourceid><addsrcrecordid>eNp1kDtPwzAURi0EolXpyIoisbAE_E48VlV5SJVYYLYc50a4ygs7GfrvcZTSAQkv9pXP_ex7ELol-JFSkj1Z8CnFFKeYyuwCLSnmNJWMsMvzGYsFWodwwHHJnCtBr9GCMRnbBFmiza6qnDX2mNjahOCmYnBdm3RV0nQl-DYZvsCb3kFIXJs0Yz24voYk2Bp8F1y4QVeVqQOsT_sKfT7vPrav6f795W272aeWEzykOc9JRhgoxSue4aIgAFJamQkqJMlLEFLSMhesqExeWJVLo4hVKo93jFvBVuhhzu199z1CGHTjgoW6Ni10Y9CUKyolycSE3v9BD93o2_g7HYcW8U3Gs0ilM2XjHMFDpXvvGuOPmmA96dVRr5706klv5O9OqWPRQHmmf2VGQM1ANQ6jh2AdtBb0XMUOZ10L_4T_ACmihw4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2515675347</pqid></control><display><type>article</type><title>Efficacy classification of modern therapies in multiple sclerosis</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Samjoo, Imtiaz A ; Worthington, Evelyn ; Drudge, Christopher ; Zhao, Melody ; Cameron, Chris ; Häring, Dieter A ; Stoneman, Dee ; Klotz, Luisa ; Adlard, Nicholas</creator><creatorcontrib>Samjoo, Imtiaz A ; Worthington, Evelyn ; Drudge, Christopher ; Zhao, Melody ; Cameron, Chris ; Häring, Dieter A ; Stoneman, Dee ; Klotz, Luisa ; Adlard, Nicholas</creatorcontrib><description>The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines.
Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate.
For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used.
Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy.</description><identifier>ISSN: 2042-6305</identifier><identifier>EISSN: 2042-6313</identifier><identifier>DOI: 10.2217/cer-2020-0267</identifier><identifier>PMID: 33620251</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Antibodies ; Bans ; cladribine ; Cladribine - therapeutic use ; Classification ; Clinical trials ; disease-modifying therapy ; Drug dosages ; Humans ; Meta-analysis ; Monoclonal antibodies ; Multiple sclerosis ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; network meta-analysis ; Neurology ; ocrelizumab ; ofatumumab ; ozanimod ; Patients ; Recurrence ; relapsing multiple sclerosis ; treatment guidelines</subject><ispartof>Journal of comparative effectiveness research, 2021-04, Vol.10 (6), p.495-507</ispartof><rights>2021 Chris Cameron</rights><rights>2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-8481713e994f470bb1ee66c67525618de5662d853bfa8bc986a91c99818d34c53</citedby><cites>FETCH-LOGICAL-c410t-8481713e994f470bb1ee66c67525618de5662d853bfa8bc986a91c99818d34c53</cites><orcidid>0000-0003-1415-8055 ; 0000-0001-6912-1685 ; 0000-0003-3613-760X ; 0000-0003-1659-2082 ; 0000-0001-9721-3069 ; 0000-0002-3891-5367</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33620251$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Samjoo, Imtiaz A</creatorcontrib><creatorcontrib>Worthington, Evelyn</creatorcontrib><creatorcontrib>Drudge, Christopher</creatorcontrib><creatorcontrib>Zhao, Melody</creatorcontrib><creatorcontrib>Cameron, Chris</creatorcontrib><creatorcontrib>Häring, Dieter A</creatorcontrib><creatorcontrib>Stoneman, Dee</creatorcontrib><creatorcontrib>Klotz, Luisa</creatorcontrib><creatorcontrib>Adlard, Nicholas</creatorcontrib><title>Efficacy classification of modern therapies in multiple sclerosis</title><title>Journal of comparative effectiveness research</title><addtitle>J Comp Eff Res</addtitle><description>The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines.
Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate.
For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used.
Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy.</description><subject>Antibodies</subject><subject>Bans</subject><subject>cladribine</subject><subject>Cladribine - therapeutic use</subject><subject>Classification</subject><subject>Clinical trials</subject><subject>disease-modifying therapy</subject><subject>Drug dosages</subject><subject>Humans</subject><subject>Meta-analysis</subject><subject>Monoclonal antibodies</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>network meta-analysis</subject><subject>Neurology</subject><subject>ocrelizumab</subject><subject>ofatumumab</subject><subject>ozanimod</subject><subject>Patients</subject><subject>Recurrence</subject><subject>relapsing multiple sclerosis</subject><subject>treatment guidelines</subject><issn>2042-6305</issn><issn>2042-6313</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kDtPwzAURi0EolXpyIoisbAE_E48VlV5SJVYYLYc50a4ygs7GfrvcZTSAQkv9pXP_ex7ELol-JFSkj1Z8CnFFKeYyuwCLSnmNJWMsMvzGYsFWodwwHHJnCtBr9GCMRnbBFmiza6qnDX2mNjahOCmYnBdm3RV0nQl-DYZvsCb3kFIXJs0Yz24voYk2Bp8F1y4QVeVqQOsT_sKfT7vPrav6f795W272aeWEzykOc9JRhgoxSue4aIgAFJamQkqJMlLEFLSMhesqExeWJVLo4hVKo93jFvBVuhhzu199z1CGHTjgoW6Ni10Y9CUKyolycSE3v9BD93o2_g7HYcW8U3Gs0ilM2XjHMFDpXvvGuOPmmA96dVRr5706klv5O9OqWPRQHmmf2VGQM1ANQ6jh2AdtBb0XMUOZ10L_4T_ACmihw4</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Samjoo, Imtiaz A</creator><creator>Worthington, Evelyn</creator><creator>Drudge, Christopher</creator><creator>Zhao, Melody</creator><creator>Cameron, Chris</creator><creator>Häring, Dieter A</creator><creator>Stoneman, Dee</creator><creator>Klotz, Luisa</creator><creator>Adlard, Nicholas</creator><general>Future Medicine Ltd</general><scope>FUMOA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1415-8055</orcidid><orcidid>https://orcid.org/0000-0001-6912-1685</orcidid><orcidid>https://orcid.org/0000-0003-3613-760X</orcidid><orcidid>https://orcid.org/0000-0003-1659-2082</orcidid><orcidid>https://orcid.org/0000-0001-9721-3069</orcidid><orcidid>https://orcid.org/0000-0002-3891-5367</orcidid></search><sort><creationdate>20210401</creationdate><title>Efficacy classification of modern therapies in multiple sclerosis</title><author>Samjoo, Imtiaz A ; Worthington, Evelyn ; Drudge, Christopher ; Zhao, Melody ; Cameron, Chris ; Häring, Dieter A ; Stoneman, Dee ; Klotz, Luisa ; Adlard, Nicholas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-8481713e994f470bb1ee66c67525618de5662d853bfa8bc986a91c99818d34c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Bans</topic><topic>cladribine</topic><topic>Cladribine - therapeutic use</topic><topic>Classification</topic><topic>Clinical trials</topic><topic>disease-modifying therapy</topic><topic>Drug dosages</topic><topic>Humans</topic><topic>Meta-analysis</topic><topic>Monoclonal antibodies</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>network meta-analysis</topic><topic>Neurology</topic><topic>ocrelizumab</topic><topic>ofatumumab</topic><topic>ozanimod</topic><topic>Patients</topic><topic>Recurrence</topic><topic>relapsing multiple sclerosis</topic><topic>treatment guidelines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Samjoo, Imtiaz A</creatorcontrib><creatorcontrib>Worthington, Evelyn</creatorcontrib><creatorcontrib>Drudge, Christopher</creatorcontrib><creatorcontrib>Zhao, Melody</creatorcontrib><creatorcontrib>Cameron, Chris</creatorcontrib><creatorcontrib>Häring, Dieter A</creatorcontrib><creatorcontrib>Stoneman, Dee</creatorcontrib><creatorcontrib>Klotz, Luisa</creatorcontrib><creatorcontrib>Adlard, Nicholas</creatorcontrib><collection>Future Medicine (Open Access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of comparative effectiveness research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Samjoo, Imtiaz A</au><au>Worthington, Evelyn</au><au>Drudge, Christopher</au><au>Zhao, Melody</au><au>Cameron, Chris</au><au>Häring, Dieter A</au><au>Stoneman, Dee</au><au>Klotz, Luisa</au><au>Adlard, Nicholas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy classification of modern therapies in multiple sclerosis</atitle><jtitle>Journal of comparative effectiveness research</jtitle><addtitle>J Comp Eff Res</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>10</volume><issue>6</issue><spage>495</spage><epage>507</epage><pages>495-507</pages><issn>2042-6305</issn><eissn>2042-6313</eissn><abstract>The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines.
Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate.
For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used.
Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>33620251</pmid><doi>10.2217/cer-2020-0267</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-1415-8055</orcidid><orcidid>https://orcid.org/0000-0001-6912-1685</orcidid><orcidid>https://orcid.org/0000-0003-3613-760X</orcidid><orcidid>https://orcid.org/0000-0003-1659-2082</orcidid><orcidid>https://orcid.org/0000-0001-9721-3069</orcidid><orcidid>https://orcid.org/0000-0002-3891-5367</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2042-6305 |
| ispartof | Journal of comparative effectiveness research, 2021-04, Vol.10 (6), p.495-507 |
| issn | 2042-6305 2042-6313 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2492661755 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Antibodies Bans cladribine Cladribine - therapeutic use Classification Clinical trials disease-modifying therapy Drug dosages Humans Meta-analysis Monoclonal antibodies Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis, Relapsing-Remitting - drug therapy network meta-analysis Neurology ocrelizumab ofatumumab ozanimod Patients Recurrence relapsing multiple sclerosis treatment guidelines |
| title | Efficacy classification of modern therapies in multiple sclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T06%3A59%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20classification%20of%20modern%20therapies%20in%20multiple%20sclerosis&rft.jtitle=Journal%20of%20comparative%20effectiveness%20research&rft.au=Samjoo,%20Imtiaz%20A&rft.date=2021-04-01&rft.volume=10&rft.issue=6&rft.spage=495&rft.epage=507&rft.pages=495-507&rft.issn=2042-6305&rft.eissn=2042-6313&rft_id=info:doi/10.2217/cer-2020-0267&rft_dat=%3Cproquest_cross%3E2515675347%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2515675347&rft_id=info:pmid/33620251&rfr_iscdi=true |